Fate Therapeutics Reports New Employee Incentive Awards Under Nasdaq Listing Rule 5635(c)(4) Via Investing.com
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: NASDAQ: ), a clinical-stage biopharmaceutical company dedicated to delivering a pipeline of first-in-class pluripotent stem cell (iPSC)-derived cellular immunotherapies for patients with cancer and autoimmune diseases, today announced that on October 1, 2024 the Company will grant units restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly hired non-management employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and were granted under the Company’s Amended and Restated Equity Compensation Plan as an incentive for new employees entering employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, and 25% of the shares underlying each RSU award vest on each grant anniversary, subject to the employee being continuously employed by the Company on each vesting date.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering a pipeline of first-in-class pluripotent stem cell (iPSC)-based cell immunotherapies for patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in the creation of multi-engineered iPSC lines and in the manufacturing and clinical development of off-the-shelf cellular products. The Company’s pipeline includes iPSC-derived natural killer (NK) cells and T-cell products, which are selectively engineered, include novel regulators of cell function, and are intended to bring multiple therapies to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact person:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
